Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Properties of Rozibafusp alfa, a Bispecific Inhibitor of BAFF and ICOSL: Analyses of Phase 1 Clinical Trials.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical pharmacology and therapeutics"
DOI: 10.1002/cpt.2929
Abstract: Rozibafusp alfa (AMG 570) is a first-in-class bispecific IgG2-peptide fusion designed to inhibit inducible T-cell costimulator ligand (ICOSL) and B-cell activating factor (BAFF). The pharmacokinetics (PK) and pharmacodynamics (PD) of rozibafusp alfa were investigated in… read more here.
Keywords: baff; rozibafusp alfa; bispecific; icosl ... See more keywords